{
    "id": 3275,
    "fullName": "EGFR L747P",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L747P lies within the protein kinase domain of the Egfr protein (UniProt.org). L747P has been associated with drug resistance (PMID: 26339441, PMID: 29673089), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 4495,
                    "pubMedId": 26339441,
                    "title": "EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26339441"
                },
                {
                    "id": 11379,
                    "pubMedId": 29673089,
                    "title": "Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29673089"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L747P",
    "createDate": "02/21/2015",
    "updateDate": "11/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 135746,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174776_55174777delTTinsCC",
        "cDna": "c.2239_2240delTTinsCC",
        "protein": "p.L747P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16773,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring EGFR L747P demonstrated stable disease in the right upper lobe lung lesion and brain metastases following treatment with Gilotrif (afatinib) and maintained progression-free survival for more than 24 months (PMID: 30746257).",
            "molecularProfile": {
                "id": 3092,
                "profileName": "EGFR L747P"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14838,
                    "pubMedId": 30746257,
                    "title": "EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30746257"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15009,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR L747P was identified as a primary resistance mutation in a patient with lung adenocarcinoma who did not respond to Tarceva (erlotinib) treatment (PMID: 27499993).",
            "molecularProfile": {
                "id": 3092,
                "profileName": "EGFR L747P"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12121,
                    "pubMedId": 27499993,
                    "title": "Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27499993"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13959,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).",
            "molecularProfile": {
                "id": 3092,
                "profileName": "EGFR L747P"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11379,
                    "pubMedId": 29673089,
                    "title": "Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29673089"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13958,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) and Avastin (bevacizumab) combination treatment resulted in stable disease for 7 months until disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).",
            "molecularProfile": {
                "id": 3092,
                "profileName": "EGFR L747P"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11379,
                    "pubMedId": 29673089,
                    "title": "Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29673089"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17657,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Tarceva (erlotinib) treatment resulted in disease progression in a patient with non-small cell lung cancer harboring EGFR L747P (PMID: 31175009).",
            "molecularProfile": {
                "id": 3092,
                "profileName": "EGFR L747P"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15702,
                    "pubMedId": 31175009,
                    "title": "Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31175009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13957,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Iressa (gefitinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).",
            "molecularProfile": {
                "id": 3092,
                "profileName": "EGFR L747P"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11379,
                    "pubMedId": 29673089,
                    "title": "Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29673089"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13960,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Keytruda (pembrolizumab), Platinol (cisplatin), and Alimta (pemetrexed) combination treatment resulted in disease progression in a patient with CD274 (PD-L1)-positive, tumor mutational burden high lung adenocarcinoma that also harbored EGFR L747P (PMID: 29673089).",
            "molecularProfile": {
                "id": 29895,
                "profileName": "CD274 pos EGFR L747P TMB high"
            },
            "therapy": {
                "id": 6798,
                "therapyName": "Cisplatin + Pembrolizumab + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11379,
                    "pubMedId": 29673089,
                    "title": "Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29673089"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3092,
            "profileName": "EGFR L747P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29895,
            "profileName": "CD274 pos EGFR L747P TMB high",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135746,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174776_55174777delTTinsCC",
            "cDna": "c.2239_2240delTTinsCC",
            "protein": "p.L747P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}